A novel PTEN/Mutant p53/ c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy

Neoplasia (United States)

Volumn 15, Issue 8, 2013, Pages 952-965

  Huang, Xiaoping ^a   Zhang, Ying ^a   Tang, Yaqiong ^a   Butler, Napoleon ^a   Kim, Jungeun ^a   Guessous, Fadila ^a   Schiff, David ^a   Mandell, James ^a   Abounader, Roger ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; NUCLEAR FACTOR Y; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL XL; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE SEQUENCE; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84881067866     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13376     Document Type: Article

References (42)

1. Carracedo A, Alimonti A, and Pandolfi PP (2011). PTEN level in tumor suppression: how much is too little? Cancer Res 71(3), 629-633.
2. Salmena L, Carracedo A, and Pandolfi PP (2008). Tenets of PTEN tumor suppression. Cell 133, 403-414.
3. Tamura M, Gu J, Tran H, and Yamada KM (1999). PTEN gene and integrin signaling in cancer. Review. J Natl Cancer Inst 91(21), 1820-1828.
4. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, and Yamada KM (1998). Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280(5369), 1614-1617.
5. Planchon SM, Waite KA, and Eng C (2008). The nuclear affairs of PTEN. J Cell Sci 121(Pt 3), 249-253.
6. Baker SJ (2007). PTEN enters the nuclear age. Cell 128(1), 25-28.
7. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L., Sampieri K, Haveman WJ, Brogi E, et al. (2010). Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 42, 454-458.
8. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, et al. (2011). PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10(6), 1093-1101.
9. Petrella BL and Brinckerhoff CE (2009). PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma. Cancer Biol Ther 8(14), 1389-1401.
10. Li Y, Guessous F, Kwon S, Kumar M, Ibidapo O, Fuller L, Johnson E, Lal B, Hussaini I., Bao Y, et al. (2008). PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res 68(6), 1723-1731.
11. Vogelstein B and Kinzler KW (2004). Cancer genes and the pathways they control. Nat Med 10(8), 789-799.
12. Santoro R and Blandino G (2010). p53: The pivot between cell cycle arrest and senescence. Cell Cycle 9(21), 4262-4263.
13. Sullivan KD, Gallant-Behm CL, Henry RE, Fraikin JL, and Espinosa JM (2012). The p53 circuit board. Biochim Biophys Acta 1825(2), 229-244.
14. Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P, and Harris CC (2004). TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 157, 247-270.
15. Sigal A and Rotter V (2000). Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60, 6788-6793.
16. Oren M and Rotter V (2010). Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2, a001107.
17. Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G, and Blandino G (2008). Oncogenomic approaches in exploring gain of function of mutant p53. Curr Genomics 9(3), 200-207.
18. PeartMJ and Prives C (2006). Mutant p53 gain of function: the NF-Y connection. Cancer Cell 10(3), 173-174.
19. Urist M and Prives C (2002). p53 leans on its siblings. Cancer Cell 1(4), 311-313.
20. Brosh R and Rotter V (2009). When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9(10), 701-713.
21. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G., and Piaggio G (2006). Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10, 191-202.
22. Dell'Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Levrero M, Strano S., Rotter V, Oren M, and Blandino G (2011). ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters. OMICS 15(5), 305-312.
23. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, andMak TW (2001). Regulation of PTEN transcription by p53. Mol Cell 8, 317-325.
24. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, Whale AD, Martinez-Diaz H., Rozengurt N, Cardiff RD, et al. (2003). PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and-independent mechanisms. Cancer Cell 3, 117-130.
25. Tang Y and Eng C (2006). PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner. Cancer Res 66, 736-742.
26. Teodorczyk M and Martin-Villalba A (2010). Sensing invasion: cell surface receptors driving spreading of glioblastoma. J Cell Physiol 222, 1-10.
27. Mantovani R (1998). A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acids Res 26, 1135-1143.
28. Haupt Y, Maya R, Kazaz A, and Oren M (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
29. Goodman RH and Smolik S (2000). CBP/p300 in cell growth, transformation, and development. Genes Dev 14, 1533-1577.
30. Chan HM and La Thangue NB (2001). p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114, 2363-2373.
31. Thompson PR, Wang D, Wang L, Fulco M, Pediconi N, Zhang D, An W, Ge Q, Roeder RG, Wong J, et al. (2004). Regulation of the p300 HAT domain via a novel activation loop. Nat Struct Mol Biol 11, 308-315.
32. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J., Wiman KG, and Selivanova G (2002). Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8(3), 282-288.
33. Trotman LC and Pandolfi PP (2003). PTEN and p53: who will get the upper hand? Cancer Cell 3(2), 97-99.
34. Meyer N and Penn LZ (2008). Reflecting on 25 years with MYC. Nat Rev Cancer 8, 976-990.
35. Dang CV (2012). MYC on the path to cancer. Cell 149(1), 22-35.
36. Nilsson JA and Cleveland JL (2003). Myc pathways provoking cell suicide and cancer. Oncogene 22(56), 9007-9021.
37. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L., Johnson L, and Evan GI (2008). Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 14, 447-457.
38. Ghosh AK, Grigorieva I, Steele R, Hoover RG, and Ray RB (1999). PTEN transcriptionally modulates c-myc gene expression in human breast carcinoma cells and is involved in cell growth regulation. Gene 235(1-2), 85-91.
39. Smith AP, Verrecchia A, Fagà G, Doni M, Perna D, Martinato F, Guccione E., and Amati B (2009). A positive role for Myc in TGFβ-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene 28(3), 422-430.
40. Vander Heiden MG, Chandel NS, Williamson EK, Schumacker PT, and Thompson C. B (1997). Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell 91, 627-637.
41. Jiang Z, Zheng X, and Rich KM (2003). Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J Neurochem 84(2), 273-281.
42. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, and Eng C (2002). Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 32(3), 355-357.